Neimeth International Pharmaceuticals Plc has officially ended a three-year cycle of losses, reporting a decisive return to profitability for the financial year ended December 31, 2025.
According to the audited financial statements released in March 2026, the pharmaceutical giant posted a profit after tax (PAT) of N982.11 million, a staggering 211% recovery from the N885.33 million loss recorded in the 2024 fiscal year.
This financial rebound marks a significant turning point for the company, which Managing Director Valentine Okelu described as a structural shift driven by an unwavering focus on fundamentals.
The company’s revenue surged by 64% during the period, reaching N7.37 billion compared to N4.49 billion in the previous year.
This growth was bolstered by an extraordinary 14,257% jump in operating profit, which rose from N18.9 million in 2024 to N2.71 billion in 2025.
The recovery was largely attributed to a sweeping restructuring of foreign currency debts and tighter cost controls, which allowed the company to record a N48 million foreign exchange gain, a dramatic reversal from the N2 billion foreign exchange loss experienced the year prior.
Neimeth’s balance sheet also showed marked improvement, with total assets growing to N13.35 billion from N11.99 billion at the start of the year.
Net assets improved by 21% to reach N1.99 billion, reflecting the strong profit generated during the 2025 business cycle.
The company’s earnings per share (EPS) turned positive at 22.98 kobo, swinging from a loss per share of 20.72 kobo in 2024.
Investors have responded positively to these results, with Neimeth’s share price appreciating by approximately 69% between early 2025 and January 2026.
Looking ahead, the company remains committed to its 2025–2029 strategic growth plan, supported by a N20 billion capital raise approved by shareholders to fund future expansion and maintain its newly restored profitability.